MENU

GNPX Stock Genprex (GNPX, $0.23) entered Uptrend as Momentum indicator ascends above 0 level on Sep 05, 2025

A.I.dvisor
at Tickeron.com
Loading...
GNPX - Genprex
Momentum signal
Bullish Trend
Odds of UP Trend
Tickeron
Momentum signal
Price: $0.2295
Daily change: +$0.0738 (+47.4%)
Daily volume: 129.3M
Industry: Biotechnology
This indicator may be signaling that GNPX's price has momentum to move higher, since its current price exceeds the price logged 14 days ago. Traders may consider buying the stock or exploring call options. A.I.dvisor backtested 82 similar cases where GNPX's Momentum Indicator exceeded 0, and of them led to a successful outcome. Odds of Success:

Momentum Indicator for GNPX turns positive, indicating new upward trend

GNPX saw its Momentum Indicator move above the 0 level on September 05, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned positive. In of the 82 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 64 cases where GNPX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for GNPX just turned positive on September 03, 2025. Looking at past instances where GNPX's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

GNPX moved above its 50-day moving average on September 10, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for GNPX crossed bullishly above the 50-day moving average on September 16, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where GNPX advanced for three days, in of 207 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for GNPX moved out of overbought territory on September 15, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 15 similar instances where the indicator moved out of overbought territory. In of the 15 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GNPX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

GNPX broke above its upper Bollinger Band on September 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for GNPX entered a downward trend on September 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.540) is normal, around the industry mean (20.607). P/E Ratio (0.320) is within average values for comparable stocks, (53.283). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.160). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (333.412).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GNPX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GNPX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
GNPX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
A.I. Advisor
published General Information

General Information

a developer of molecular therapies for cancer treatment

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
3300 Bee Cave Road
Phone
+1 877 774-4679
Employees
26
Web
https://www.genprex.com